Sofinnova Partners closed its €725 million Crossover II fund to back later-stage European biopharma and medtech companies.

Sofinnova closes €725M Crossover II fund in Europe

Sofinnova closes €725M Crossover II fund in Europe

Image: AI-generated editorial illustration

Sofinnova Partners said on November 16, 2026 that it had closed Crossover II at €725 million, surpassing its original target and extending its crossover strategy for later-stage life sciences companies in Europe.

Sofinnova Partners has closed its Crossover II fund at €725 million, according to a November 16, 2026 announcement. The European life-sciences venture firm said the vehicle exceeded its original target and is designed to back later-stage biopharmaceutical and medtech companies as they move from clinical development toward commercialization.

Reuters described Crossover II as the firm’s second crossover fund and its largest to date, while BioPharma Dive said the vehicle is positioned for companies approaching commercialization rather than early-stage seed bets. Reuters explained that a crossover fund typically invests in private companies approaching commercialization or public listings, bridging venture capital and public-market investing.

What kind of companies will Crossover II back?

Crossover II will primarily invest in European clinical-stage biopharma and medtech companies that need capital to advance toward commercialization. Sofinnova said the strategy will also make selective investments in the United States and other international markets, but Europe remains the main focus. The firm said the fund is positioned to support roughly 15 high-growth companies.

Sofinnova said the mandate covers late-stage life sciences businesses through clinical development, global expansion and commercialization. Reuters reported that Sofinnova plans to be an active investor, helping portfolio companies with leadership, trials and listings. According to Reuters, Kinam Hong said the goal is to build companies for "successful longevity" even without mergers and acquisitions.

Which companies has Sofinnova already backed?

Sofinnova said Crossover II had already invested in Hemab Therapeutics, CellCentric and Neurent Medical when the fund close was announced. Reuters described Hemab as a rare-disease biotech, CellCentric as a developer of a multiple-myeloma drug, and Neurent Medical as a maker of a device for chronic rhinitis.

The initial portfolio fits the fund’s later-stage remit. Reuters also said the fund has already invested in those companies as it targets later-stage life sciences businesses moving toward commercialization.

Why does Sofinnova say the fund matters now?

Sofinnova framed the raise as evidence of the maturity of Europe’s life-sciences ecosystem and continued demand for growth capital. That is the firm’s own characterization, not an independent market measurement, but it aligns with broader pressure in European biopharma financing. Reuters reported that the fund close came as drugmakers pushed European governments for more spending on medicines, faster trials and policy changes to keep pace with the U.S. and China.

Reuters also reported that cash-strapped European governments are under pressure to rethink how they pay for innovative medicines. In that environment, crossover capital can be especially relevant for companies that have already cleared early scientific hurdles but still need substantial funding before a listing, sale or other liquidity event.

Sofinnova said the fund is backed by the European Tech Champions Initiative, a fund-of-funds managed by the European Investment Fund. The firm said the strategy is led by partners Joe Anderson, Kinam Hong, Cedric Moreau, Jacques Theurillat and David Evans.

The firm also pointed to its earlier crossover track record. Sofinnova said Crossover I supported LimFlow, acquired by Inari Medical; Calliditas Therapeutics, acquired by Asahi Kasei; Amolyt Pharma, acquired by AstraZeneca; and Abivax, which completed a Nasdaq listing. Reuters separately reported that the first crossover fund backed Amolyt Pharma and Abivax.

Founded in 1972 and headquartered across Paris, London and Milan, Sofinnova says it has backed more than 500 companies and now manages over €4 billion in assets across healthcare and sustainability. The new fund extends that platform into later-stage European life sciences, with the firm saying it will back companies through clinical development, global expansion and commercialization.

Sources